Vor Biopharma (VOR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.70
- Surprise
- —
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27 — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates VOR Sell at 5.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: telitacicept
- Concentration risk — Counterparty: RemeGen
- Quality below floor (1.5 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.31
- Price target
- $33.93
- Stop
- $17.03
- Upside to target
- +85.3%
- Reward-to-risk
- 6.0:1
Risk check: RSI 27 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
VOR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $992.1M
- P/E (fwd)
- -4.8
- P/E (ttm)
- 0.1
- 52-week range
- $6.50–$34.63
- Off 52-week high
- 47.1%
- RSI (14)
- 27
- Volume vs avg
- 0.35×
- Score today
- 5.4/10